Key result
Atorvastatin, but not evolocumab, significantly reduced postprandial triglyceride and apoB-48 total area under the curves by approximately 30% in healthy, normolipidemic men.
Why the study?
Does treatment with atorvastatin or evolocumab improve postprandial metabolism of triglyceride-rich lipoproteins in healthy normolipidemic men?
RCT (n=80)
Double-blind, placebo-controlled
Randomized into a 2-by-2 factorial trial
Does treatment with atorvastatin or evolocumab improve postprandial metabolism of triglyceride-rich lipoproteins in healthy normolipidemic men?
Atorvastatin, but not PCSK9 inhibition with evolocumab, improves postprandial triglyceride-rich lipoprotein metabolism by accelerating apoB-48 catabolism.
Answers are grounded in this paper and cite their sources.
Statins may confer unique postprandial TRL benefits versus evolocumab; extends evidence of their differential effects on apoB-48 metabolism.
Objective— Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) and statins are known to lower plasma LDL (low-density lipoprotein)-cholesterol concentrations. However, the comparative effects of these treatments on the postprandial metabolism of TRLs (triglyceride-rich lipoproteins) remain to be investigated. Approach and Results— We performed a 2-by-2 factorial trial of the effects of 8 weeks of subcutaneous evolocumab (420 mg every 2 weeks) and atorvastatin (80 mg daily) on postprandial TRL metabolism in 80 healthy, normolipidemic men after ingestion of an oral fat load. We evaluated plasma total and incremental area under the curves for triglycerides, apo (apolipoprotein)B-48, and VLDL (very-LDL)-apoB-100. We also examined the kinetics of apoB-48 using intravenous D3-leucine administration, mass spectrometry, and multicompartmental modeling. Atorvastatin and evolocumab independently lowered postprandial VLDL-apoB-100 total area under the curves ( P <0.001). Atorvastatin, but not evolocumab, reduced fasting plasma apoB-48, apoC-III, and angiopoietin-like 3 concentrations ( P <0.01), as well as postprandial triglyceride and apoB-48 total area under the curves ( P <0.001) and the incremental area under the curves for plasma triglycerides, apoB-48, and VLDL-apoB-100 ( P <0.01). Atorvastatin also independently increased TRL apoB-48 fractional catabolic rate ( P <0.001) and reduced the number of apoB-48–containing particles secreted in response to the fat load ( P <0.01). In contrast, evolocumab did not significantly alter the kinetics of apoB-48. Conclusions— In healthy, normolipidemic men, atorvastatin decreased fasting and postprandial apoB-48 concentration by accelerating the catabolism of apoB-48 particles and reducing apoB-48 particle secretion in response to a fat load. Inhibition of PCSK9 with evolocumab had no significant effect on apoB-48 metabolism.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2018) conducted an RCT in Healthy, normolipidemic (n=80). Atorvastatin and Evolocumab vs. Placebo was evaluated on Postprandial apoB-48 total area under the curve (AUC) (-30%, p=<0.001). Atorvastatin, but not evolocumab, significantly reduced postprandial triglyceride and apoB-48 total area under the curves by approximately 30% in healthy, normolipidemic men.
Synapse has enriched 10 related papers. Consider them for comparative context: